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Abstract: Obsessive-compulsive disorder (OCD) is a chronic anxiety disorder. While   medication 
and psychotherapy advances have been very helpful to patients, many patients do not respond 
adequately to initial trials of serotonergic medication or cognitive-behavioral therapy (CBT) 
and require multiple treatment trials or combination therapies. Comorbidity may also influence 
treatment response. The role of streptococcal infections in pediatric OCD has become an area 
of intense scrutiny and controversy. In this article, current treatment methods for OCD will 
be reviewed, with special attention to strategies for treating OCD in children and in patients 
with comorbid tic disorders. Alternative psychotherapy strategies for patients who are highly 
anxious about starting CBT, such as cognitive therapy or augmentation with D-cycloserine, will 
be reviewed. Newer issues regarding use of antibiotics, neuroleptics, and glutamate modulators 
in OCD treatment will also be explored.
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Introduction
Obsessive-compulsive disorder (OCD) is a chronic, often disabling anxiety disorder 
featuring obsessions or compulsions or, most typically, both of these.1 This common 
condition has a lifetime prevalence of 1.6%–2.3%.2,3 Onset peaks in the early 20s, 
but a smaller early-onset peak in preadolescence, much more common in boys than 
girls, may be associated with tic comorbidity.3–5 Children are more likely to present 
with compulsions alone, or to have brief compulsions atypical of adult OCD, such as 
blinking or breathing rituals.6
This paper will focus on the two major treatment strategies for OCD: cognitive-
behavioral therapy (CBT) and serotonergic medications. Indicators of quality treatment 
will be reviewed, with particular attention to the care of pediatric patients. Because of 
the high rate of treatment-resistance in OCD, some novel strategies such as cognitive 
therapy (CT) (which de-emphasizes exposure) and medication augmentation with 
neuroleptics or glutamate (GLU) modulators will also be explored.
Comorbidity and pediatric autoimmune 
neuropsychiatric disorders after streptococcus
Comorbidity with other psychiatric conditions is reported in 79.7% of patients with 
OCD and may impact treatment response.7 In adult OCD, comorbid major depression 
is seen in 54% of patients; anxiety disorders and alcohol-use disorders are also Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  common.3 In pediatric OCD, comorbidity with attention-
deficit/hyperactivity disorder (ADHD) (34%–51%) and tics 
or tic disorders (20%–80%) is also common.8,9
Over the last 15 years, controversy has arisen over 
the possible association of prepubertal-onset OCD with 
streptococcal pharyngitis, known as pediatric autoimmune 
neuropsychiatric disorders after streptococcus (PANDAS).10,11 
PANDAS is modeled on Sydenham’s chorea, a streptococcus-
triggered autoimmune disease characterized by abrupt onset 
of chorea, which is treated with antibiotic prophylaxis.12 
PANDAS, it is theorized, results when the body mounts 
an immune response against streptococcal infection but the 
antibodies attack the basal ganglia in error, triggering brain 
dysfunction. Swedo et al13 have proposed PANDAS criteria of 
(a) abrupt prepubertal onset of OCD and/or tics; (b) significant 
impairment within 48 hours of symptom onset; (c) associated 
chorea or hyperactivity; and (d) temporal association of 
exacerbations with at least two streptococcal infections. 
Positive streptococcal titers and cultures are very frequent in 
children during regional streptococcal outbreaks, triggering 
the requirement for two infection-associated exacerbations.
Parents of children with OCD may find the highly 
  publicized theory of PANDAS accessible and compelling. 
It is easy to see why families may take comfort in the 
idea that the pediatrician could treat their child with an 
antibiotic instead of the child requiring specialty care 
from a mental health care provider. However, the theory 
remains controversial. A thorough search for evidence of 
autoimmune markers in twelve children with PANDAS 
found no correlation.14 Two prospective studies, both lasting 
2 years, investigated association of streptococcal infections 
with tic and OCD symptoms in children diagnosed with 
PANDAS. One study found that new infection predicted 
a modest symptom increase,15 while the other found only 
12.5% of symptom exacerbations were linked to infections 
in the previous 4 weeks.16
Proper treatment of children with PANDAS is debated. 
Gabbay et al17 expressed concerns that 82% of patients 
diagnosed with PANDAS by community pediatricians had 
no laboratory evidence of any group A beta-hemolytic strep-
tococcal infections and were being treated inappropriately 
with antibiotics. The efficacy of such antibiotic prophylaxis 
of PANDAS remains suspect following publication of two 
antibiotic prophylaxis studies.18–20 Current expert consensus 
guidelines recommend that children with PANDAS be treated 
with antibiotics only during acute streptococcal infections 
and that they be treated for OCD concomitantly with standard 
OCD medication and psychotherapy.10,21
Treatment strategies: exposure  
and response prevention therapy
Controlled studies of OCD treatment have focused on 
  exposure and response prevention (ERP) therapy and on sero-
tonergic medications. Studies typically use the gold-  standard 
structured clinician rating instrument, the Yale–Brown 
Obsessive-Compulsive Scale (Y-BOCS), or the Children’s 
Y-BOCS (CY-BOCS), to monitor response.22,23 Y-BOCS/
CY-BOCS scores range from 0 to 40, with a score of 17 or 
higher considered clinically significant. Significant treatment 
response is typically defined as reduction in Y-BOCS/CY-
BOCS score by at least 25%–35%.
ERP therapy is the preferred form of psychotherapy for 
OCD, particularly for patients with milder symptoms and 
minimal comorbidity. ERP therapy is recommended as a 
first-line treatment for adults with OCD who are able to 
complete the treatment protocol or who prefer not to take 
medications;24 however, patients with significant comorbid 
depression or anxiety may find ERP therapy difficult. ERP 
therapy is also preferred as the first-line treatment for   children 
and adolescents, particularly those patients with milder 
symptom severity (ie, CY-BOCS score ,19) and minimal 
comorbidity.25,26 Pediatric patients with comorbid major 
depression or disruptive behavior disorders such as ADHD 
or oppositional defiant disorder may be less responsive to 
ERP therapy. Sexual or religious obsessions may be less 
responsive to ERP therapy than other obsession types in 
children; tic comorbidity has demonstrated variable impact 
on ERP therapy response in pediatric studies.27
ERP therapy, a specialized form of CBT, has a mean 
effect size of 1.13 in adults and 1.45 in children.26,28 
  Approximately 55% of patients completing 10–20 sessions of 
ERP therapy report substantial improvement.29 ERP therapy 
has demonstrated efficacy in multiple controlled studies for 
adults30–34 and children.35–37 The combination of exposure 
to feared situations and prevention of ritualization has been 
found superior to the components of ERP only.38
Due to a shortage of well-trained, experienced providers, 
high-quality ERP therapy may be difficult for many patients 
to access. Blanco et al39 estimated that less than 10% of 
OCD patients receive adequate ERP therapy. Quality ERP 
therapy features prolonged, graded, personalized exposure 
to avoided stimuli, such as sources of contamination for 
patients obsessed with germs. The patient and the provider 
develop a hierarchy of feared situations, starting with expo-
sure to moderately feared situations, and targeting highly 
feared situations midway through treatment, to allow time 
to work through more difficult exposures.40 Quality exposure Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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sessions last at least 90 minutes and feature strict response 
prevention during and between sessions.41 Better-quality 
therapy is provided by experienced ERP therapists, who 
may use manualized protocols, including “How I ran OCD 
off my land” for pediatric patients.42
Pediatric ERP therapy has demonstrated efficacy in 
multiple controlled studies, with positive results maintained 
for up to 24 months of follow-up.36 Positive results have 
even been reported for 31 children, aged from 5 to 8 years, 
participating in a controlled study comparing family ERP 
therapy with family relaxation therapy.43 March44 emphasizes 
taking great care in obtaining the child’s input regarding 
design of the exposure sessions, as “what appears to be 
graded exposure to the therapist may turn out to be flooding 
for the child.”44 Pediatric ERP therapy often includes 
extinction, or the removal of parents’ positive reinforcement 
of OCD symptoms (ie, providing reassurance when the child 
is anxious, or even aiding in ritual completion each morning 
so that the family is not late for work and school). Extinction 
may be more effective if the child helps design the extinction 
plan. New forms of positive reinforcement, such as prizes 
and reward ceremonies, are built into the ERP therapy for 
children.
ERP therapy formats: visit 
frequency, individual, group,  
and family sessions
Typical ERP therapy is delivered in 15–20 weekly or twice 
weekly sessions. Patients travelling from out of town may 
prefer intensive treatment (eg, 12 hours of therapy deliv-
ered in 5 days) although some patients may worry this 
model is too intense or brief.45 Storch et al,27 in a study of 
56 patients, found intensive daily CBT was as effective as 
weekly sessions.
Group therapy is less expensive for patients than indi-
vidual sessions. Group therapy may be especially helpful for 
socially isolated patients, particularly hoarders, and it has 
shown similar efficacy to individual sessions.46
Family ERP therapy may be especially helpful in targeting 
family accommodation of OCD symptoms, reported in 70% 
of families.47 In a study of 65 families, daily reassurance was 
provided by 56% of families; daily participation in rituals, 
associated with greater symptom severity, was seen in 46%.48 
Significant reduction of family accommodation is associated 
with better treatment outcome.47 In a pilot group family 
ERP therapy study, high parental involvement in exposure 
homework improved outcome.49 Parents participating in 
family ERP therapy act as coaches between therapist-assisted 
exposures, they target accommodations at home, and they 
work on their own distress associated with their child’s 
exposure practice.43 Two long-term follow-up studies of 
family ERP therapy have demonstrated that the majority 
of patients maintained significant symptom reduction for at 
least 18 months following the therapy.36,50
CT has been investigated as an alternative to ERP therapy. 
CT is focused on altering dysfunctional beliefs about   intrusive 
thoughts. These thoughts are seen in 90% of the normal 
population51 but OCD patients misinterpret these thoughts 
as “having serious implications, for which the person having 
the thoughts could be personally responsible.”52 CT for OCD 
emphasizes cognitive strategies over exposure; however, it 
has been criticized for not being a “pure” form of CT in that 
many CT studies include some exposure. Some patients may 
find CT less anxiety provoking and more palatable because 
it de-emphasizes exposure.53 In direct comparisons, ERP 
therapy has outperformed CT.40
Hoarding
Hoarding is a controversial symptom in OCD research. 
Hoarding may be neurobiologically distinct from other 
forms of OCD, with some researchers proposing classifying 
hoarding separately from OCD in the Diagnostic and 
Statistical Manual of Mental Disorder (5th edition), as 
“compulsive hoarding.”54 Genetic studies suggest that 
hoarding is common and highly heritable, particularly in 
women.55 While hoarding symptoms are reported by a 
substantial minority of patients with OCD, populations 
of patients with significant hoarding symptoms who lack 
other OCD symptoms have been identified.56 Older women 
living alone are particularly likely to present for clinical 
care of hoarding behaviors; many may have comorbid 
social phobia.57 While hoarded clutter may interfere with 
their functioning, patients with hoarding symptoms often 
do not seek care and find their hoarding ego-syntonic.58 
Neuroimaging studies of OCD patients with prominent 
hoarding symptoms have demonstrated greater activation of 
bilateral anterior ventromedial prefrontal cortex (VMPFC) in 
response to hoarding-related provocation than in nonhoarding 
OCD control subjects.59 VMPFC lesions in humans have been 
reported to trigger new hoarding behaviors.60–62
Hoarding symptoms have proven less responsive to 
typical ERP therapy and OCD medications than other 
symptom clusters.63 New treatment models for hoarding 
symptoms feature a mixture of in-office sessions and 
individual home visits to deal with accumulated clutter and 
use saving inventories and clutter image ratings, rather than Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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the Y-BOCS.64 Hoarding patients appear to have particular 
issues with social isolation, treatment refusal (37% of patients 
in one study), and low compliance. In a manualized, wait-list 
controlled study, 41% of patients demonstrated significant 
improvement.63 Therapeutic strategies included motivational 
interviewing to reduce ambivalence about homework and 
therapy attendance. Training in organizing, decision making, 
and problem solving was provided, as well as exposure 
to decrease acquiring and increase discarding behaviors. 
Published manuals regarding hoarding behaviors include 
Buried in Treasures: Help for Compulsive Acquiring, Saving, 
and Hoarding (a self-help book)65 and Compulsive Hoarding 
and Acquiring: Therapist Guide.66
Medication treatment of OCD
The United States Food and Drug Administration (FDA) has 
approved serotonin reuptake inhibitors (SRIs) – including 
clomipramine (CMI) and the selective serotonin reuptake 
inhibitors (SSRIs) fluoxetine (FLX), fluvoxamine (FLV), 
paroxetine (PAR), and sertraline (SER) – for OCD   treatment. 
CMI is approved for age 10 and older; FLV , age 8 and older; 
FLX, age 7 and older; and SER, age 6 and older. The effect 
size for SRIs is 0.91 for adults and 0.46 in children.67,68 
While the advent of serotonergic medications has been a 
great boon for patients with OCD, typically 40%–68% of 
patients do not respond to the first SRI trial, and “responders” 
may continue to struggle with very intense symptoms and 
remain syndromic.69
An adequate SRI trial for OCD should last 10–12 weeks, 
with at least 4–6 weeks at the maximum tolerated dose. SRIs 
are recommended as first-line treatment for adults with severe 
OCD or who are not able to complete ERP therapy because 
of comorbidity or inability to access ERP therapy services.24 
SRIs are considered first-line treatment for children and 
teenagers with more severe OCD (CY-BOCS score $19), 
preferably in combination with ERP therapy.
SSRis in OCD
SSRIs are well-established treatments for OCD and are 
preferred to CMI because they are less likely to be toxic in 
overdose, to prolong the corrected QT interval and trigger 
cardiac arrhythmia, or to cause seizures. Relatively high doses 
of several SSRIs have been required in adult studies – ie, 
FLX or PAR doses of at least 40 mg and escitalopram of at 
least 20 mg.70–73 Comparison studies among SSRIs are rare, 
and there is a lack of convincing evidence that one SSRI is 
more effective than the others.
The efficacy of SSRI treatment of pediatric OCD is 
well established, although there have been more intense 
safety concerns regarding antidepressants in the younger 
  population. The FDA issued a black-box warning regarding 
elevated risk of suicidal ideation or attempts in patients under 
the age of 25 years treated with antidepressants, following 
review of 24 placebo-controlled studies. No completed 
suicides were reported.74,75 While the OCD studies, unlike 
depression studies, did not reveal increased risk of sui-
cidal ideation or behavior in the SSRI-treated children and 
teenagers, suicidal ideation in a 13-year-old with comorbid 
major depression triggered premature discontinuation of an 
early FLX study.76,77
CMi in OCD
CMI was the first medication to demonstrate OCD efficacy. 
In multiple meta-analyses of adult medication trials, it 
has demonstrated superior efficacy to SSRIs.69,78–80 This 
superiority also holds true in pediatric meta-analyses, with 
an effect size of 0.85 as compared with 0.46 for all SRIs 
(SSRIs plus CMI).26,68 Patients treated with CMI should 
have electrocardiogram and blood levels checked regularly 
and should be aware of the risk of orthostatic hypotension, 
seizures, and urinary retention. Because of these side effects, 
CMI is typically reserved for patients who have not responded 
adequately to at least two SSRI trials. In a controlled pediatric 
CMI study, the maximum dose was 3 mg/kg, or 200 mg daily, 
in 10- to 17-year-olds.81
Intravenous (IV) CMI has been studied in adults, on an 
investigational basis, typically in inpatients with severe OCD 
not responsive to multiple prior medication trials, including 
oral CMI.82–84 IV CMI may be better tolerated than the 
oral form and it provides 4- to 14-fold higher peak plasma 
concentrations.83 Response rates in this highly refractory 
population have been low; for instance, in one placebo-
controlled study of 46 patients, 21% of treated patients 
versus 0% of controls were responders after 2 weeks of daily 
infusions, with 58% maintaining responder status on oral 
CMI 1 month later.85
Tic comorbidity and SRi treatment
Tic comorbidity has been a particular concern in pediatric 
OCD studies. In a pediatric PAR study, 75% of patients   without 
comorbidity were responders (at least 25% CY-BOCS score 
reduction); however, response rate fell to 56% for patients with 
comorbid ADHD and to 53% for patients with a tic disorder.86 
In the large-scale controlled Pediatric Obsessive-Compulsive Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
489
OCD management
Disorder Treatment Study (POTS), while SER was more 
effective than placebo for patients without tics, SER did not 
differentiate from placebo for 17 patients with comorbid 
chronic tic disorders.35,87 Tic comorbidity has been reported 
to reduce response to FLV but not to CMI.88,89
Serotonin-norepinephrine reuptake 
inhibitors
The efficacy of CMI, a serotonergic tricyclic antidepressant 
with both serotonergic and noradrenergic action, has 
triggered interest in the serotonin-norepinephrine reuptake 
inhibitors (SNRIs) as anti-OCD medications, particularly 
venlafaxine (VEN). SNRIs lack CMI’s antagonism of alpha-
1-adrenergic, cholinergic, and histaminergic receptors, and 
thus are less likely to trigger orthostatic hypotension, dry 
mouth, and urinary retention.90 In a small adult comparator 
study, VEN showed similar efficacy to CMI, and was better 
tolerated.91 In the only placebo-controlled VEN trial at a target 
dose of 225 mg daily in adults, a trend toward improvement 
was noted at 8 weeks, a short duration for an OCD trial. 
Progress was measured using the Clinical Global Impression 
scale only, not the Y-BOCS.92 One hundred and thirty-four 
patients completed a large study comparing VEN with PAR.93 
Y-BOCS reduction was similar in the treatment arms, with 
a mean decrease of 7.2 ± 7.5 points with VEN and 7.8 ± 5.4 
points with PAR.
Mirtazapine and duloxetine have each demonstrated 
efficacy in small open studies.90,94
SRi augmentation strategies
Medication augmentation strategies are useful for patients 
who are treatment resistant, typically defined as those who 
have not responded adequately to at least two SSRI trials 
and to CMI. The most promising medication classes for SRI 
augmentation are the neuroleptics and GLU modulators.
Neuroleptic augmentation in OCD
When second-generation antipsychotics were developed, it 
was hoped that their combined serotonergic and dopaminergic 
effects might prove useful as OCD monotherapy. However, 
second-generation neuroleptic monotherapy has not been 
effective for OCD and may even cause OCD-like symptoms 
in previously unaffected patients with schizophrenia.95–98 
In one study, schizophrenic patients developing obsessive-
compulsive symptoms on clozapine had higher clozapine 
and norclozapine blood levels than patients not developing 
those symptoms.97
Neuroleptic augmentation increases metabolism in key 
brain areas implicated in OCD. In a functional neuroimaging 
study, 15 patients with OCD who had not responded to two 
SRI trials were randomized to risperidone (RIS) or placebo 
augmentation. Patients treated with RIS demonstrated 
increased metabolic rates in the striatum, cingulate gyrus, 
prefrontal cortex, and thalamus. Those patients with low 
metabolic rates in the striatum before RIS augmentation were 
likely to respond favorably to RIS.99
RIS, a second-generation antipsychotic, and haloperidol 
(HAL), a first-generation antipsychotic, were the best-
performing neuroleptics in Bloch et al’s100 meta-analysis of 
OCD augmentation agents. In this analysis of nine double-
blind, placebo-controlled trials of HAL, RIS, quetiapine, 
and olanzapine, patients with comorbid tics were especially 
likely to respond to augmentation. In the meta-analysis, one-
third of patients not responding to two SRI trials became 
responders with neuroleptic addition. In the sole HAL study, 
patients with tics responded to a mean dose of 6.2 ± 3 mg 
daily.101 Three positive RIS augmentation studies used doses 
ranging from 0.5 to 3 mg for most patients.102–104 Data were 
inconclusive for quetiapine and olanzapine augmentation. 
Quetiapine is the most studied neuroleptic in OCDs, with 
four controlled studies, only one of which demonstrated 
clinical significance.100,105
Response to neuroleptic augmentation is much quicker 
than response to a SRI alone; most patients demonstrate 
response within 4 weeks. While long-term studies of 
neuroleptic augmentation have not been published, long-term 
maintenance of the neuroleptic appears necessary, as relapse 
was seen in 15 of 18 patients discontinuing neuroleptic 
augmentation in a chart review and was particularly likely 
in the first 2 months following discontinuation.106 The risks 
and benefits should be considered carefully by patients and 
providers due to the risks of weight gain, dyslipidemia, 
diabetes, and tardive dyskinesia.
Pediatric trials of neuroleptic augmentation are limited 
to two case series evaluating RIS. In the larger series, four 
of 17 adolescents had Y-BOCS score reductions of at least 
15%.107,108
Stimulant use in OCD treatment
Stimulant medications, particularly amphetamines, have 
been studied in OCD, typically as SSRI/SNRI augmentation 
agents. Mechanism of action of these agents in OCD is 
unclear, as stimulants induce compulsive rituals,109 but 
has been postulated to relate to pro-serotonergic effects.110 Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Patients have been reported to demonstrate OCD-symptom 
reduction following single stimulant doses.110,111 A double-
blind study comparing dextroamphetamine augmentation 
with caffeine control found 58% of patients were Y-BOCS 
responders to caffeine, compared with 50% of patients to 
dextroamphetamine.112 At this point, stimulant use in OCD 
would be considered investigational.
GLU modulators as OCD  
augmentation agents
Evidence is mounting that GLU, “the most common 
excitatory neurotransmitter”113 may play an important role in 
the pathophysiology of OCD. A study of eleven medication-
naïve children with OCD, for instance, demonstrated that the 
OCD patients had higher caudate concentrations of GLU plus 
glutamine than normal controls on proton magnetic resonance 
spectroscopy. Subsequent PAR treatment normalized GLU 
activity.114
Medications modulating GLU have been marketed as 
treatments for amyotrophic lateral sclerosis (riluzole [RIL]), 
Alzheimer’s disease (memantine [MEM]), and seizure 
disorders (topiramate, lamotrigine). Clinical OCD studies 
have focused on using GLU modulators as SRI augmentation 
agents. One such agent, RIL, reduces GLU release and blocks 
gamma-aminobutyric acid reuptake. RIL triggers hepatic 
transaminase elevations in at least 50% of patients, and 2% 
demonstrate transaminase elevations to five times normal 
levels, a trigger to RIL withdrawal in amyotrophic lateral 
sclerosis studies.115
RIL has been studied in two adult case series totaling 
26 patients. Transient transaminase increases in a small number 
of patients did not necessitate study withdrawal, occurring 
as late as 20 weeks after RIL initiation. Approximately 
half of the patients demonstrated at least a 35% Y-BOCS 
score reduction, including some patients with hoarding 
symptoms. Significant reductions in Hamilton Depression 
Rating Scale and Hamilton Anxiety Scale scores were also 
reported.115,116
In an open-label pediatric OCD trial, 100–200 mg daily of 
RIL was added to stable anti-OCD medications for 12 weeks. 
RIL was well tolerated by the six youths with a mean age of 
14.4 years and mean CY-BOCS reduction was 39%.117 This 
trial was so promising that it inspired a 12-week controlled 
pediatric RIL trial that is ongoing at the National Institute of 
Mental Health (NIMH) and includes patients with comorbid 
autism spectrum disorders. Final data for this study have not 
been published. However, two of the NIMH patients have 
developed pancreatitis, one of whom had unusually high RIL 
blood levels, which might have related to the recent addition 
of FLV. Another child with premorbid liver steatosis was 
withdrawn due to transaminase elevation.118
MEM is a noncompetitive N-methyl-D-aspartate GLU 
receptor antagonist that limits GLU neurotoxicity. Unlike 
RIL, MEM lacks hepatotoxicity. In a 12-week open-label 
study, adults stable on a SRI for at least 12 weeks were treated 
with adjunctive MEM titrated from 5 mg daily to 10 mg twice 
daily by week 4. Six of eleven study completers had Y-BOCS 
reductions of at least 25%; reduction in depression ratings 
was not correlated with Y-BOCS reduction.119
Topiramate has also shown promise as an OCD 
  augmentation agent in two open-label adult case series 
of 26 patients combined; no patients developed renal 
stones.120,121 Mean dose ranged from 237.5 to 253.1 mg/day. 
However, topiramate has also been reported to trigger de 
novo OCD symptoms in two patients, one of whom cleared 
promptly with topiramate cessation.122 The other was a 
19-year-old who required citalopram treatment following 
topiramate withdrawal.123 Lamotrigine at 100 mg daily for 4 
weeks was effective for only one of four patients in another 
open-label case series.124
Benefits of combination therapy 
(ERP therapy plus medication)
A small number of placebo-controlled trials have explored the 
relative efficacy of SRIs, ERP therapy, or their combination. 
ERP therapy and combination therapy have proven superior 
to SRIs in child and adult populations. In adults, Foa 
et al33 compared combination therapy, CMI therapy (to a 
maximum of 250 mg daily), and ERP therapy in 86 patients. 
While all treatments were superior to placebo, ERP therapy 
and combination therapy were equivalent, and both were 
superior to CMI only. In the pediatric POTS study, SER (to a 
maximum of 200 mg daily) was compared with ERP therapy 
and combination therapy.35 In total, 112 youths completed 
the study. Combination therapy was superior at one of two 
sites to ERP therapy only, ERP therapy was superior to SER 
at both sites, and SER was superior to placebo. The authors 
concluded that youths with OCD should begin treatment with 
ERP therapy only or with ERP therapy plus a SSRI.
Medication pretreatment has also been explored as a 
way to make patients less anxious about ERP therapy, as at 
least 25% of patients seeking therapy have been reported 
to decline participation once offered.29,125 D-cycloserine 
(DCS), an N-methyl-D-aspartate receptor partial agonist, 
is being investigated for this role. Dosage administered 
and time of dose before session has varied among studies; Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Rothbaum126 recently suggested that lower doses (ie, 
100–125 mg) administered close to the start of the session 
may be helpful, as at higher doses, DCS acts as a full glycine 
site antagonist and has been found to exacerbate symptoms 
of schizophrenia.127
DCS has not been helpful in all studies and appears more 
likely to reduce early patient fear ratings or speed up the 
“slope of recovery” in early sessions than to enhance ultimate 
symptom reduction.128–131
Surgical treatment for treatment-
resistant OCD
For patients with severe and highly treatment-resistant OCD, 
two surgical methods are available that have demonstrated 
efficacy for some patients not responding to medication 
and psychotherapy. The less invasive option is deep brain 
stimulation of the anterior limb of the internal capsule or 
the adjacent striatum.132 The more invasive treatment of last 
resort is ventral capsular/ventral striatal capsulotomy.133
Conclusion
ERP therapy is the first-line treatment for most patients with 
OCD, although lack of availability of high-quality services 
limits its use. SSRIs used at adequate doses for at least 
10–12 weeks are reasonable first options for patients unable 
to complete or obtain ERP therapy. Patients not responsive 
to first rounds of monotherapy may benefit from the com-
bination of ERP therapy and a SSRI. CMI is an appropriate 
option for patients who do not respond to two adequate 
SSRI trials, but it requires close monitoring due to the risk 
of seizures and cardiac toxicity. Neuroleptic augmentation 
of SRIs is a reasonable option for some treatment-resistant 
patients, especially those with tics. While GLU modulators 
are promising, controlled trials in children and adults are 
needed before their role in OCD therapy is clear. Patients 
whose significant anxiety prevents them from initiating 
ERP therapy may benefit from DCS treatment early in ERP 
therapy or from CT; however, these methods also warrant 
further research.
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